Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6 by Jensen, B L et al.
Many breast cancer patients with oestrogen receptor-positive
primary tumours benefit from treatment with the anti-oestrogen
tamoxifen (Mouridsen et al, 1978; Osborne et al, 1980). However,
upon prolonged treatment with tamoxifen, resistant tumours will
eventually develop. Recently, novel pure antagonistic compounds
have been produced, to replace or supplement tamoxifen as first-
or second-line endocrine treatment for breast cancer patients
(Wakeling, 1993; Osborne et al, 1995). One of these agents, the
pure steroidal anti-oestrogen ICI 182780, has been found to be a
potent growth inhibitor of oestrogen-sensitive tissues in vivo and
oestrogen-sensitive cell lines in vitro (Wakeling et al, 1991;
Lykkesfeldt et al, 1994). Moreover, the ICI 182780 compound is
effective for treatment of breast cancer patients refractory to
tamoxifen therapy (Howell et al, 1995). Although initially very
effective, treatment with the pure steroidal anti-oestrogen may
postpone but not circumvent development of anti-oestrogen
resistance (Lykkesfeldt et al, 1995; Osborne et al, 1995). Several
different mechanisms have been proposed to account for anti-
oestrogen resistance (Katzenellenbogen, 1991; Lykkesfeldt,
1996), and clinical evidence support some of them. In this study,
we have compared the ICI 182780-resistant MCF-7 subline, MCF-
7/182R-6, with the parental ICI 182780-sensitive MCF-7 cell line
with respect to the following parameters: ER content and binding
characteristics, oestradiol and ICI 182780 regulation of ER and
progesterone receptor (PgR) mRNA and protein, oestradiol
requirement for in vitro cell growth, and gene expression in the
presence of ICI 182780 to elucidate the mechanisms involved in
anti-oestrogen resistance in this cell line.
MATERIAL AND METHODS
Cell lines and growth experiments
The MCF-7 cell line has been obtained from the Breast Cancer
Task Force Cell Culture Bank, Mason Research Institute
(Worchester, MA, USA). It has been adapted to grow in DME/F12
medium supplemented with 1% heat inactivated fetal calf serum
(FCS) (Gibco, Life Technologies), 6 ng ml—1 bovine insulin (Novo-
Nordic, Copenhagen, Denmark) and 2.5 mM Glutamax (Life
Technologies) (Briand and Lykkesfeldt, 1984). The MCF-7/182R-6
cell line, which is resistant to the pure anti-oestrogen ICI 182780
(Zeneca Pharmaceuticals, Macclesfield, UK), has been established
in this laboratory by long-term treatment of MCF-7 cells with
10—7 M ICI 182780, and it is maintained in DME/F12 medium
supplemented with 1% FCS, 6 ng ml—1 insulin, 2.5 mM Glutamax
and 10—7 M ICI 182780 (Lykkesfeldt et al, 1995). Growth medium
was changed every 2 or 3 days, and the cultures were subcultivated
by trypsinization once a week (split ratio about 20).
MCF-7/182R-6 cells were withdrawn from ICI 182780 1 week
before onset of a growth experiment. MCF-7 and MCF-7/182R-6
cells used for growth experiments were seeded with 2´104 cells
per well in 24-well multidishes (Nunc, Roskilde, Denmark) in
medium with 5% FCS from which steroids have been removed by
a charcoal treatment (Horwitz and McGuire, 1978). Experimental
medium was added after 2 days (day 0) and cell number deter-
mined at the indicated days. Experimental medium was renewed in
the remaining wells after each cell counting.
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Competition assay and Scatchard analysis
Cytosols of MCF-7 and MCF-7/182R-6 cells were prepared as
previously described (Briand and Lykkesfeldt, 1984). Cytosols
were incubated at 4°C for 18—20 h in the presence of 1.5 nM
[3H] 17-b-oestradiol (Amersham, Buckinghamshire, UK), and
different concentrations of (E)-cis-4-hydroxy-tamoxifen (Research
Biochemicals International, Natick, MA, USA), tamoxifen, ICI
182780 (Zeneca), or oestradiol (Collaborative Research) in 96-well
microtitre plates (Nunc). Unbound hormone was removed using
dextran-coated charcoal (DCC). The results were corrected for
non-specific binding by subtraction of the counts bound in a 100-
fold excess of non-radioactive oestradiol, and expressed as a
percentage of the maximal binding with [3H]oestradiol alone. The
molar concentrations leading to 50% competition (IC50) were deter-
mined from competition curves. The equilibrium dissociation
constant (KD) was determined by the charcoal technique/Scatchard
plot procedure (EORTC Breast Co-operative Group, 1980).
Western analysis
MCF-7 and MCF-7/182R-6 cells were propagated in T25 flasks
(Nunc) in ICI 182780-free medium 12 days before Western
analysis to avoid any reminiscent effects. After treatment with
either 10—9 M oestradiol or 10—7 M ICI 182780, the 70—80%
confluent monolayer cultures were harvested using 0.5 ml RIPA
buffer (100 mM sodium chloride, 20 mM Trizma-Base, 1% Triton
X-100, 0.5% sodium desoxycholate, 0.1% SDS, and 1 mM
sodium-EDTA, pH 8.0). Seventy micrograms of total protein per
sample (determined by the Bio-Rad protein assay kit, Munich,
Germany) were run on 15% sodium dodecyl sulphate polyacry-
lamide gel electrophoresis (SDS-PAGE) gels. The proteins were
transferred to an Immobilon-P membrane (Millipore, Bedford,
MA, USA) by electroblotting. Immunostaining was carried out
using a primary monoclonal mouse anti-human ER antibody (1D5,
DAKO, Glostrup, Denmark) and a secondary polyclonal rabbit
anti-mouse IgG peroxidase conjugated antibody (P260, DAKO).
The enhanced chemiluminescence (ECL) detection system
(Amersham) was used for visualization of the ER protein as
described in the manufacturer￿s manual.
Northern analysis
MCF-7 and MCF-7/182R-6 cell cultures were treated with either
10—9 M oestradiol or 10—7 M ICI 182780 for 0, 1/4, 1/2, 1, 3, 6, 24 or
48 h before harvest with Trizol Reagent (Life Technologies). Total
RNA was isolated from the Trizol Reagent lysate as recommended
by the supplier. Poly(A)+RNA was isolated with the Oligo (dT)25
coupled magnetic beads (Dynal, Oslo, Norway) according to the
manufacturer￿s manual. Two micrograms of poly(A)+RNA were
denatured with glyoxal/DMSO solution, run on a 1.2% agarose gel
and transferred to a nylon membrane (Nytran 13N, Schleicher &
Schuell, Dassel, Germany). The probes used for Northern
hybridization were cDNA probes of the 1.8-kb EcoRI fragment of
the hER from pSG5-HEGO (Tora et al, 1989), the 3.6-kb BamHI
fragment from the hPgR, and the 1.1-kb PstI fragment of 36B4
from MCF-7 cloned into the pBR322 vector (Laborda, 1991)
respectively. The probe for the differentially expressed transcript
indicated by the arrow in Figure 5 was obtained by reamplification
(using the same primer set and PCR conditions as for the screening)
of DNA extracted from the area in the gel corresponding to the
indicated band on the autoradiograph. The probes were randomly
labelled with [a-32P]dCTP (Amersham) using the Megaprime DNA
labelling system (Amersham). Northern blots were hybridized
using 1.25´106 c.p.m. randomly labelled probe ml—1 QuickHyb
Hybridization Solution (Stratagene). The blots were exposed to
Kodak X-Omat AR-5 films. Each blot was also exposed to a
PhosphorImager screen (Molecular Dynamics), for 1—4 days,
before quantification using the ImageQuant software (Molecular
Dynamics).
Differential display screening
RNA used for reverse transcriptase polymerase chain reaction
(RT-PCR) differential display screening (Liang and Pardee, 1992)
was isolated from MCF-7 and MCF-7/182R-6 cells using Trizol
Reagent. Cells were grown either in absence or presence of 10—7 M
ICI 182780 for 3 days before preparation. The RNA was treated
with DNAase I (Promega) to remove possible contamination with
DNA. The differential display screening was performed as recom-
mended by the producer of the RNA Image kit (GenHunter,
Nashville, TN, USA), but using [33P]dATP instead of [35S]dATP.
cDNA was prepared from the DNAase-treated RNA using one of
three downstream primers [(T)11-G, -A, or -C, supplied in the kit]
and the Moloney Murine Leukemia Virus Reverse Transcriptase
(MMLV-RT, Gibco). The cDNA product was amplified for 40
cycles using one of eight arbitrary upstream primers (supplied in
the kit) and the AmpliTaq DNA Polymerase (Perkin-Elmer). The
RT and the PCR reactions were performed in a Perkin-Elmer 9600
thermocycler. The RT-PCR products were run on a 5% denaturing
polyacrylamide gel. All reactions were run in duplicate and all 24
primer combinations were tested. After electrophoresis, the gel
was vacuum dried and placed in a film cassette with intensifying
screen for autoradiography using Kodak X-Omat AR-5 films.
Reamplified, gel-purified DNA fragments were used as templates
for solid-phase DNA sequencing as described previously (Madsen
et al, 1995).
RESULTS
Expression and binding characteristics of the ER
protein in MCF-7 and MCF-7/182R-6 cells
Previous work from our group has documented that loss of ER is
not involved in the emergence of the ICI 182780-resistant pheno-
type in our cell lines established in vitro (Lykkesfeldt et al, 1995).
However, the ER content in the resistant MCF-7/182R-6
cells is only 221 ± 58 fmol mg—1 cytosol protein compared with
616 ± 93 fmol mg—1 cytosol protein in the parent MCF-7 cells,
demonstrating a reduced expression of the ER protein in the resis-
tant cell line (Larsen et al, 1997). Whether or not the ER protein
Table 1 Molar concentration of oestradiol and anti-oestrogen leading to
50% competition (IC50) with 3H-labelled 17-b-oestradiol for binding to ER in
cytosol preparations from MCF-7 and MCF-7/182R-6 cells
Hormone MCF-7 (M) MCF-7/182R-6 (M)
17-b-oestradiol 2.1 ´ 10–9 1.7 ´ 10–9
ICI 182780 1.5 ´ 10–7 1.0 ´ 10–7
(E)-cis-4-Hydroxy-tamoxifen 3.6 ´ 10–7 3.3 ´ 10–7
Tamoxifen 1.2 ´ 10–6 1.1 ´ 10–6388 BL Jensen et al
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expressed in MCF-7/182R-6 cells is functional primarily depends
on its ability to bind the physiological ligand oestradiol. Scatchard
plot analysis of results from a ligand binding assay with oestradiol
revealed very similar KD values of 0.65 ´ 10—10 M and 1.34 ´ 10—10
M for MCF-7 and MCF-7/182R-6 respectively. The possibility that
the oestrogen receptors, expressed in the MCF-7/182R-6 cell line,
were unable to bind ICI 182780 or other anti-oestrogens like 4-
hydroxy-tamoxifen and tamoxifen was investigated using a
competition assay. It was clearly demonstrated that both oestradiol
and anti-hormones were competing with 3H-labelled oestradiol for
binding to the ER, each at identical molar concentrations in both
cell lines (Table 1).
Effect of oestradiol or ICI 182780 on the ER protein
expression
To determine how the ER protein is affected by oestradiol and ICI
182780, time course Western blot analyses were carried out. In
both MCF-7 and MCF-7/182R-6 cells, only one ER species was
present, corresponding to the 65-kDa wild-type ER protein (Figure
1). The ER protein level decreased significantly in the cells after a
few hours of treatment with either 10—9 M oestradiol or 10—7 M ICI
182780 (Figure 1). In MCF-7 cells, total disappearance of the ER
protein was found upon 48 h of treatment with oestradiol, or upon
3 h of treatment with ICI 182780. A very slight increase in ER
level was seen after 24 and 48 h of treatment with ICI 182780. In
MCF-7/182R-6 cells, both oestradiol and ICI 182780 rapidly
down-regulated the ER protein content to a minimum after 3—6 h.
However, unlike MCF-7 cells, reappearance of ER protein after 24
and 48 h of ICI 182780 treatment was not observed in MCF-
7/182R-6 cells. The level of ER protein in MCF-7/182R-6 cells is
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Figure 1 Effect of oestradiol or ICI 182780 on ER protein content in MCF-7
and MCF-7/182R-6 cells. Cell lysates were prepared at the indicated
treatment times with either 10–9 M oestradiol (A and C) or 10–7 M ICI 182780
(B and D). Seventy micrograms of protein were loaded in each lane on a 15%
SDS-PAGE gel. The ER protein was detected using a primary monoclonal
mouse anti-human ER antibody (1D5), a secondary polyclonal rabbit anti-
mouse IgG peroxidase conjugated antibody (P260), and the immunocomplex
was visualized using the enhanced chemiluminescence (ECL) detection
system (Amersham)
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Figure 2 Effect of 10–9 M oestradiol on the ER mRNA and PgR mRNA expression and of 10–7 M ICI 182780 on the ER mRNA expression in MCF-7 (A) and
MCF-7/182R-6 cells (B). RNA was prepared from monolayer cell cultures after 0, 1/4, 1/2, 1, 3, 6, 24, and 48 h of treatment with either oestradiol or ICI 182780.
The RNA was run on an agarose gel, blotted onto a nylon membrane, before the amount of transcripts of ER, PgR and 36B4 were determined by hybridization
with randomly labelled plasmid probes. The 36B4 mRNA was used as an internal control and the PhosphorImager scan values were normalized to this
transcript. The ratio of either ER or PgR and 36B4 was expressed as a percentage of the control ratio obtained in RNA samples from non-steroid-treated cellsDifferential gene regulation in MCF-7/182R-6 cells 389
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significantly lower than in MCF-7 cells, and a small increase may
escape detection by this method. Cells followed upon removal of
ICI 182780 from the growth medium exhibited no reappearance of
ER protein within 48 h (data not shown), suggesting that longer
growth in ICI 182780-free medium is required to re-establish a
normal ER level.
Effect of oestradiol or ICI 182780 on the ER and PgR
mRNA expression
To elucidate whether the effect of oestradiol and ICI 182780 on the
ER protein were exerted at the transcriptional or the translational
level, and to examine the possible induction of the PgR mRNA
synthesis, time course Northern blotting experiments were carried
out. In Figure 2, graphical representations of data from
PhosphorImager scanning of Northern blots (Figure 3), expressed
as the ratios between the specific transcript and the 36B4 ribo-
somal phosphoprotein, are shown. The mRNA levels (in
percentage of control RNA from non-steroid-treated cells) are
expressed as a function of time. In MCF-7 cells, ER mRNA was
down-regulated by 10—9 M oestradiol to 30% after about 30 min,
and the expression remained low throughout the entire time
interval of 48 h. In contrast, in the resistant cell line, the ER
mRNA was down-regulated to 50% within the first few hours, but
tended to increase after 24 and 48 h. The PgR expression was
increased approximately threefold after 24 h of oestradiol treat-
ment in the parental cell line. However, the resistant cell line had
totally lost the ability to express, and to induce the expression of
the PgR mRNA upon oestradiol treatment, levels above the detec-
tion level for Northern blotting. The ER mRNA expression was
unaffected by the addition of 10—7 M ICI 182780 until after 24 and
48 h, when an up-regulation to 240% and 270% of the control
level was seen in MCF-7 and MCF-7/182R-6 cells respectively.
Cultures of both cell lines treated with ICI 182780 even for short
time intervals (of less than 1 h) did not express measurable
amounts of PgR mRNA (data not shown). The effects described
above were found in three individual experiments for each of the
two cell lines. Photos of representative Northern blots, with the
characteristic absence of PgR induction in the resistant cell line
upon oestradiol treatment, are shown in Figure 3.
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Figure 3 Northern blots of RNA from MCF-7 (A) and MCF-7/182R-6 cells
(B) treated with oestradiol. Two micrograms of poly(A)+RNA from each cell
line were analysed by Northern hybridization. 32P-labelled plasmid probes for
ER and PgR were used, and the blots were rehybridized with 36B4 probe as
internal control. The sizes of the individual transcripts are shown, the ER
mRNA is 6.5 kb, the PgR-A mRNAs are 5.6 and 3.0 kb, the PgR-B mRNAs
are 11.5, 6.5, 4.8 and 4.0 kb, and the 36B4 mRNA is 1.2 kb
Figure 4 For the growth experiments, MCF-7 or MCF-7/182R-6 cells were
seeded in multi-dishes (2´104 cells per well). Two days after seeding, the
medium containing 5% oestradiol-deprived FCS was changed to
experimental medium supplemented either with: no steroid (n n); 10–9 M
oestradiol (l l); or 10–7 M ICI 182780 (l). At day 0, 3, 4, 5, 6 and 7 after the
addition of the experimental medium, the cells in four wells from each culture
were counted in a Bürker-Türck chamber, and cell numbers were expressed
as a function of time. Standard deviations are indicated with vertical bars
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Growth of MCF-7 and MCF-7/182R-6 cells in oestradiol-
deprived medium
The precise mechanism(s) behind the capacity of MCF-7/182R-6
cells to tolerate ICI 182780 well is not known at present. To inves-
tigate whether the MCF-7/182R-6 cell line has evolved to an
oestradiol-independent or an oestradiol-hypersensitive phenotype,
growth experiments in medium containing 5% FCS, stripped for
oestrogen compounds, were conducted (Figure 4). MCF-7 cells
grow slowly in oestradiol-deprived medium, whereas MCF-7
cultures supplied with 10—9 M oestradiol grow rapidly with a cell
population doubling time of about 20 h. MCF-7 cells treated with
10—7 M ICI 182780 display a small initial increase in cell number,
but after 4 days of treatment a decrease in cell number, due to cell
death, is observed. In contrast, the MCF-7/182R-6 cells grow
equally well in the absence or the presence of oestradiol. Cell
population doubling time is 24 h for the first 5 days. These results
indicate that the anti-oestrogen-resistant cell line has lost the
oestradiol requirement for growth in vitro. However, because
oestrogen-deprived serum contains low levels of oestrone and
oestrone sulphate (Briand and Lykkesfeldt, 1984), which may be
converted to oestradiol, the ability of MCF-7/182R-6 cells to grow
in oestradiol-deprived medium may either be due to a significantly
reduced requirement for oestradiol (hypersensitivity) (Masamura
et al, 1995) or to development of oestrogen-independent cell
growth. To elucidate this, MCF-7/182R-6 cells were grown with
10—7 M ICI 182780. Such a high concentration of the pure anti-
oestrogen should be more than sufficient to compete totally with
any low amount of oestrogen, and consequently the observed rapid
growth of MCF-7/182R-6 cells under these conditions (Figure 4)
demonstrates that the resistant cell line is oestrogen-independent
for in vitro cell growth.
Differential display screening of cells grown in
presence or absence of ICI 182780
To search for gene products which may be responsible for the
development of anti-oestrogen resistance in vitro, differential
display screening was initiated (Liang and Pardee, 1992). Control
experiments confirming the reproducibility between different
passages of cells were performed before the screening was carried
out with only one passage of each cell line. Relatively few gene
expression differences were identified as MCF-7 and MCF-
7/182R-6 RNA from cultures grown in the presence or the absence
of 10—7 M ICI 182780 for 3 days were compared. In total, we have
performed 24 separate RT-PCR reactions and found 35 differ-
ences. Figure 5 shows a typical autoradiograph, in which each
reaction has been run in duplicate, displaying gene expression in
MCF-7 and MCF-7/182R-6 cells. The differentially expressed gene
product indicated with an arrowhead has been isolated from the
gel, reamplified and sequenced. Northern analysis showed that this
specific gene product is down-regulated in MCF-7, whereas it is
modestly up-regulated in MCF-7/182R-6 cells upon ICI 182780
treatment (Figure 6). It was found that the gene product, indicated
with the arrowhead in Figure 5, is homologous to human mito-
chondrial DNA control region (access code J01415). The DNA
sequence, corresponding to our mRNA, represents a so far uniden-
tified gene product. Several other gene expression differences than
the one displayed in Figure 5 are currently being investigated.
DISCUSSION
A panel of anti-oestrogen-resistant cell lines have been developed
in this laboratory upon long-term treatment of MCF-7 cells with
different anti-oestrogens (Lykkesfeldt et al, 1995). The MCF-7
breast cancer cell line, which expresses high levels of ER, is
responsive to mitogenic and growth inhibitory signals induced by
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Figure 5 Autoradiogram showing expressed gene products in MCF-7 and
MCF-7/182R-6. Genes expressed in MCF-7 cells are shown in lanes 1 and 2,
and genes expressed in MCF-7/182R-6 cells are shown in lanes 3 and 4. The
samples run in lanes 1 and 3 originate from cells maintained in control
medium (1% FCS), whereas the samples run in lanes 2 and 4 are from cells
treated with ICI 182780 for 3 days before RNA preparation and differential
display. C indicates control RNA from rat embryo fibroblasts supplied in the
differential display kit from GenHunter. The primer set used for the duplicate
reactions was upstream primer number 3 and downstream primer H-T11-C
Figure 6 Relative content of a differentially expressed specific mRNA
determined by Northern analysis and PhosphorImager quantification.
Northern blot analysis of the differentially expressed transcript, identified from
the differential display gel shown in Figure 5. The numbers 1–4 correspond to
RNA samples obtained from MCF-7 (1 and 2) and MCF-7/182R-6 (3 and 4)
cells grown either in absence (1 and 3) or presence (2 and 4) of 10–7 M ICI
182780 for 3 days before RNA preparation. The PhosphorImager
quantification of the differentially expressed transcripts is related to the
internal control transcript, 36B4Differential gene regulation in MCF-7/182R-6 cells 391
British Journal of Cancer (1999) 79(3/4), 386–392 © Cancer Research Campaign 1999
oestrogens and anti-oestrogens respectively. Therefore, MCF-7 and
sublines hereof provide excellent model systems for the study of
hormonal regulation of ER in human breast cancer. Most tumours
responding to endocrine therapy with anti-oestrogens are ER posi-
tive. However, the stability of this phenotype may not be permanent
(Johnston et al, 1995; Clarke and Br￿nner, 1996; Robertson, 1996).
This fact prompted us to investigate whether loss of ER or severely
changed regulation and function of the ER could explain the emer-
gence of the ICI 182780-resistant phenotype of MCF-7/182R-6
cells. Furthermore, we compared the parental MCF-7 cell line and
the MCF-7/182R-6 cell line with regard to growth requirements and
differentially expressed gene products, and to gain more knowledge
of which precise mechanism(s) might be involved in the develop-
ment of anti-oestrogen resistance.
Quantitative ER determinations have shown that the parental
cell line expresses approximately threefold more ER than MCF-
7/182R-6 cells (Larsen et al, 1997). The hormone/anti-hormone
binding studies revealed similar Kd values for oestradiol binding
and identical IC50 concentrations for competition of oestradiol
with the anti-oestrogens ICI 182780, 4-hydroxy-tamoxifen and
tamoxifen. Therefore, we conclude that the anti-oestrogen resis-
tance is not caused by impaired receptor function with respect to
binding of oestrogen or anti-oestrogen.
Western blot analyses disclosed that oestradiol as well as ICI
182780 were able to down-regulate the content of ER protein effec-
tively in both cell lines, after only a few hours of treatment (Figure
1). These semiquantitative results are in accordance with the
observed  t1/2 of 3 h and 0.9 h for the ER in the presence of oestra-
diol or ICI 164384, reported earlier (Dauvois et al, 1992; Borr￿s et
al, 1996). The level of regulation of the ER expressed in our cell
lines was determined by comparing the time course Western blots
with corresponding Northern blots. It was found that in MCF-7
cells oestradiol down-regulated the ER mRNA to about 30% within
the first hours of treatment, as reported by others (Saceda et al,
1988; Berkenstam et al, 1989; Berthois et al, 1990; Borr￿s et al,
1994). However, the initial reduction in the ER protein level in both
cell lines more than corresponds with the reduction to 30—50% in
the mRNA level, suggesting that oestradiol regulates ER protein
content both by reducing the mRNA synthesis and also by destabi-
lizing the protein, e.g. via ER processing as described by Horwitz
and McGuire (1978). We have no explanation for the observation
that MCF-7/182R-6 cells appear to differ from MCF-7 cells with
respect to re-establishment of control ER mRNA and protein level
after oestradiol treatment for 24 and 48 h. Total disappearance of
ER protein in both cell lines after 3 h of ICI 182780 treatment
without reduction in ER mRNA level is in agreement with observa-
tions of others (Gibson et al, 1991; Dauvois et al, 1992; Pink and
Jordan, 1996), indicating that the antagonistic effect of the pure
anti-oestrogens ICI 164384 and ICI 182780 is due to ER protein
loss. The fact that the ER, by which ICI 182780 exerts its function,
has maintained the same pattern of regulation in the resistant cell
line compared with the MCF-7 cell line, both regarding ER protein
and ER mRNA, indicates that the resistant cell line, when growing
with high ICI 182780 concentration, may compensate for the
blocked ER pathway by inducing other mitogenic signals in the
cells. The activation of such mitogenic pathways may account for
the ability of MCF-7/182R-6, opposed to MCF-7, to grow well in
the presence of ICI 182780.
Analysis of PgR mRNA expression revealed significant differ-
ences between the two cell lines. Whereas the PgR mRNA expres-
sion was increased about threefold in the parental cell line upon
48 h of oestradiol treatment, no detectable transcripts were present
in poly(A)+RNA preparations from MCF-7/182R-6 cells either
before or after oestradiol treatment (Figure 3). These findings agree
with previous reports both from this laboratory and others, showing
that several anti-oestrogen-resistant cell lines lack PgR expression
or express reduced levels of PgR (Lykkesfeldt et al, 1994, 1995;
Herman and Katzenellenbogen, 1996; Pink and Jordan, 1996). It is
very likely that a certain threshold level of ER is necessary for the
induction and synthesis of ER-regulated gene products, such as the
PgR (van Agthoven et al, 1994). The required level of ER for
induction of transcription may vary from gene to gene, as shown
for vascular endothelial growth factor and c-fos (Hyder et al, 1997)
and supported by our observation that the cathepsin D and pS2
genes display a normal oestrogen response in anti-oestrogen-resis-
tant cell lines (Larsen et al, 1997). Therefore, we presume that the
reduced ER level in the MCF-7/182R-6 cells is insufficient for PgR
induction. However, other intracellular changes such as lack of
cofactors essential for the ER-governed transcription of the PgR
gene, or mutations in the promoter region of the PgR gene leading
to decreased initiation of transcription, may also account for the
lost PgR expression and inducibility in the MCF-7/182R-6 cell line.
To investigate to which degree of oestrogen independence the
MCF-7/182R-6 cells have evolved, cell growth experiments were
performed using serum from which endogenous oestrogens have
been removed by a charcoal treatment. The resistant cell line
exhibits a decreased requirement for oestradiol because the cell
line is able to grow well in oestradiol-deprived medium. Similar
results have been reported for a hydroxy-tamoxifen-resistant cell
line (Herman and Katzenellenbogen, 1996), but the reason for the
decreased oestradiol requirement remains to be determined.
Oestrogen-deprived serum contains small amounts of oestrone and
oestrone sulphate (Briand and Lykkesfeldt, 1984), and the MCF-
7/182R-6 cell line may be able to respond to low amounts of
oestrogen as shown for a MCF-7 subline in which oestradiol depri-
vation caused hypersensitivity (Masamura et al, 1995). Our obser-
vation that MCF-7/182R-6 cells are able to grow equally well in
oestradiol-deprived medium with and without 10—7 M ICI 182780
eliminated the possibility of hypersensitivity to oestradiol because
the pure anti-oestrogen is able to compete completely with low
concentration of reminiscent oestrogen. The conclusion from our
growth experiments is that the MCF-7/182R-6 cells grow as
oestrogen-independent cells in vitro. It should be mentioned that
MCF-7/182R-6 cells require oestrogen for growth in vivo in
athymic nude mice (Lykkesfeldt et al, 1995; Larsen et al, 1997),
although the appearance of slow-growing tumours in some of the
intact animals without oestrogen supplementation indicates a
reduced requirement for oestrogen (Lykkesfeldt et al, 1995).
Analysis of differentially expressed genes was performed to
investigate the similarity of the two cell lines. In general, the gene
expression is very much the same in the two cell lines, but 35
differentially expressed transcripts were displayed, as DNA-free
RNA from MCF-7 and MCF-7/182R-6 cells treated or non-treated
with ICI 182780 for 3 days were compared. According to the
manufacturer, our 24 RT-PCR reactions should display about 10%
of all 15 000 genes assumed to be expressed in a cell. Our finding
of 35 differences indicates that approximately 2.5% of the genes
are differently regulated in MCF-7 and MCF-7/182R-6 cells after 3
days of ICI 182780 treatment. The identity of the majority of these
displayed differences still remains to be determined, but a few
differentially expressed transcripts have been identified. One of
the identified mRNAs represents a mitochondrial gene, which392 BL Jensen et al
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according to a DNA database search may encode a protein with a
high level of homology to prokaryotic membrane lipoproteins. We
believe that this gene product, rather than being the reason for the
development of anti-oestrogen resistance, is the consequence of
the altered expression of one or more so far unidentified gene
product(s). The identity of such ￿anti-oestrogen resistance-
inducing gene products￿ is still unknown, but once identified they
will provide us with valuable knowledge of the precise mecha-
nism(s) by which anti-oestrogen resistance emerges and hopefully
also supply us with some indication to what might be done to
avoid or postpone the development of resistance in vivo.
In conclusion, our results demonstrate that the ICI 182780 resis-
tant cell line, MCF-7/182R-6, displays oestrogen-independent
growth in vitro, lack of PgR expression and diffential expression of
some genes. However, the cell line remains closely related to the
parental MCF-7 cell line, with respect to expression, function and
regulation of the ER protein and ER mRNA. These findings,
together with similar findings by others (Herman and
Katzenellenbogen, 1996; Larsen et al, 1997), lead us to suggest that
the resistant cell line represents an early stage in the development of
a totally hormonal and growth factor-independent phenotype.
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